The upregulation of genes such as ELOVL3 and PECR in non‐lesional skin and ELOVL3 and FADS2 in plaque skin may improve lipid barrier function, suggesting that bevacizumab could potentially alleviate epidermal barrier dysfunction and limit disease progression in psoriasis. The gene discussed is FADS2; the disease is psoriasis.